Volunteer Login Study Team Login

Print

Lay Description

The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

Category

  • Behaviors and Mental Disorders
  • Children's Health
  • Wounds and Injuries
IRB Number
20140412XT
NCT Number
ct.gov registration not required
Open to Enrollment
Yes

Eligibility

Eligible Ages
30 Years -
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Study Contact


Regulatory Point of Contact
Juliana Lopez
9565886655
lopezj21@uthscsa.edu

Principal Investigator
Joseph Mccormick